Vanguard Group Inc. Has $20.78 Million Stock Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Vanguard Group Inc. has increased its stake in Eyepoint Pharmaceuticals by 0.8%, owning approximately 5.57% of the company, valued at about $20.78 million.
• Eyepoint Pharmaceuticals reported a loss of ($0.85) EPS for the last quarter, missing analysts' expectations and generated revenue of $5.33 million.
• Research analysts maintain a consensus "Buy" rating for Eyepoint Pharmaceuticals, with an average target price of $26.86, despite a recent drop in share value.

Vanguard Group Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,834,368 shares of the company's stock after buying an additional 31,141 shares during the quarter. Vanguard Group Inc. owned about 5.57% of Eyepoint Pharmaceuticals worth $20,782,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of Eyepoint Pharmaceuticals by 3,174.4% during the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after acquiring an additional 9,936 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at about $76,000. Arizona State Retirement System lifted its stake in Eyepoint Pharmaceuticals by 12.7% in the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after buying an additional 1,877 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Eyepoint Pharmaceuticals during the fourth quarter worth about $91,000. Finally, New York State Common Retirement Fund grew its position in shares of Eyepoint Pharmaceuticals by 208.8% during the 1st quarter. New York State Common Retirement Fund now owns 20,114 shares of the company's stock worth $109,000 after buying an additional 13,600 shares during the period. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Trading Down 1.0%

Shares of EYPT stock traded down $0.12 on Thursday, hitting $11.88. 742,789 shares of the stock were exchanged, compared to its average volume of 618,499. The firm has a market capitalization of $818.89 million, a P/E ratio of -4.43 and a beta of 1.93. The business has a 50-day moving average of $10.63 and a 200 day moving average of $8.00. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.98.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). The firm had revenue of $5.33 million during the quarter, compared to analyst estimates of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. As a group, research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EYPT. Mizuho cut their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. Royal Bank Of Canada started coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 target price on the stock. Chardan Capital restated a "buy" rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Finally, HC Wainwright raised their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $26.86.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.